Josep Miquel i Macaya i Francesc Roig i Ferran. Epistolari entre dos apassionats pels llibres (1956-1981)

Autor: Figueras Capdevila, Narcís, Grau i Pujol, Josep M. T.

Publikováno v: Quaderns de la Selva; 2010: Núm.: 22; p. 199-208

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______613::ef44e7fc2f1b1907338ca8170ec26086
http://www.raco.cat/index.php/QuadernsSelva/article/view/225280

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

RhoA downregulation in the murine intestinal epithelium results in chronic Wnt activation and increased tumorigenesis.

Autor: Dopeso H; Group of Biomedical Research in Digestive Tract Tumors, Vall d'Hebron University Hospital Research Institute (VHIR), Universitat Autònoma de Barcelona, 08035 Barcelona, Spain., Rodrigues P; Group of Biomedical Research in Digestive Tract Tumors, Vall d'Hebron University Hospital Research Institute (VHIR), Universitat Autònoma de Barcelona, 08035 Barcelona, Spain., Cartón-García F; Group of Biomedical Research in Digestive Tract Tumors, Vall d'Hebron University Hospital Research Institute (VHIR), Universitat Autònoma de Barcelona, 08035 Barcelona, Spain., Macaya I; Group of Biomedical Research in Digestive Tract Tumors, Vall d'Hebron University Hospital Research Institute (VHIR), Universitat Autònoma de Barcelona, 08035 Barcelona, Spain., Bilic J; Group of Biomedical Research in Digestive Tract Tumors, Vall d'Hebron University Hospital Research Institute (VHIR), Universitat Autònoma de Barcelona, 08035 Barcelona, Spain., Anguita E; Group of Biomedical Research in Digestive Tract Tumors, Vall d'Hebron University Hospital Research Institute (VHIR), Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.; Group of Molecular Oncology, Biomedical Research Institute of Lleida (IRBLleida), 25198 Lleida, Spain., Jing L; Group of Biomedical Research in Digestive Tract Tumors, Vall d'Hebron University Hospital Research Institute (VHIR), Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.; Group of Molecular Oncology, Biomedical Research Institute of Lleida (IRBLleida), 25198 Lleida, Spain., Brotons B; Group of Molecular Oncology, Biomedical Research Institute of Lleida (IRBLleida), 25198 Lleida, Spain., Vivancos N; Group of Molecular Oncology, Biomedical Research Institute of Lleida (IRBLleida), 25198 Lleida, Spain., Beà L; Group of Molecular Oncology, Biomedical Research Institute of Lleida (IRBLleida), 25198 Lleida, Spain., Sánchez-Martín M; Instituto de Investigación Biomédica de Salamanca (IBSAL), 37007 Salamanca, Spain.; Servicio de Transgénesis, Nucleus, Universidad de Salamanca, 37007 Salamanca, Spain.; Departamento de Medicina, Universidad de Salamanca, 37007 Salamanca, Spain., Landolfi S; Translational Molecular Pathology, Vall d'Hebron University Hospital Research Institute (VHIR), Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain., Hernandez-Losa J; Translational Molecular Pathology, Vall d'Hebron University Hospital Research Institute (VHIR), Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain., Ramon Y Cajal S; Translational Molecular Pathology, Vall d'Hebron University Hospital Research Institute (VHIR), Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain., Nieto R; Group of Biomedical Research in Digestive Tract Tumors, Vall d'Hebron University Hospital Research Institute (VHIR), Universitat Autònoma de Barcelona, 08035 Barcelona, Spain., Vicario M; Digestive System Research Unit, Vall d'Hebron University Hospital Research Institute (VHIR), 08035 Barcelona, Spain., Farre R; Department of Chronic Diseases and Metabolism (CHROMETA), Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven 3000, Belgium., Schwartz S Jr; Group of Drug Delivery and Targeting, Vall d'Hebron University Hospital Research Institute (VHIR), Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.; Clinical Biochemistry Department, Vall d'Hebron University Hospital, 08035 Barcelona, Spain., van Ijzendoorn SCD; Department of Biomedical Sciences of Cells and Systems, Section Molecular Cell Biology, University of Groningen, University Medical Center Groningen, Groningen 9713 GZ, the Netherlands., Kobayashi K; Department of Molecular Genetics, Institute of Biomedical Sciences, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan., Martinez-Barriocanal Á; Group of Biomedical Research in Digestive Tract Tumors, Vall d'Hebron University Hospital Research Institute (VHIR), Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.; Group of Molecular Oncology, Biomedical Research Institute of Lleida (IRBLleida), 25198 Lleida, Spain., Arango D; Group of Biomedical Research in Digestive Tract Tumors, Vall d'Hebron University Hospital Research Institute (VHIR), Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.; Group of Molecular Oncology, Biomedical Research Institute of Lleida (IRBLleida), 25198 Lleida, Spain.

Publikováno v: IScience [iScience] 2024 Mar 01; Vol. 27 (4), pp. 109400. Date of Electronic Publication: 2024 Mar 01 (Print Publication: 2024).

Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer.

Autor: Macaya I; University of Navarra, Center for Applied Medical Research, Program in Solid Tumors, Pamplona, Spain., Roman M; University of Navarra, Center for Applied Medical Research, Program in Solid Tumors, Pamplona, Spain.; Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA, USA., Welch C; University of Navarra, Center for Applied Medical Research, Program in Solid Tumors, Pamplona, Spain., Entrialgo-Cadierno R; University of Navarra, Center for Applied Medical Research, Program in Solid Tumors, Pamplona, Spain., Salmon M; Experimental Oncology Group, Molecular Oncology Program, Spanish National Cancer Center (CNIO), Madrid, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Santos A; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; H12O-CNIO Lung Cancer Clinical Research Unit, Instituto de Investigación Hospital 12 de Octubre & Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain., Feliu I; University of Navarra, Center for Applied Medical Research, Program in Solid Tumors, Pamplona, Spain., Kovalski J; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.; Department of Urology, University of California San Francisco, San Francisco, CA, USA., Lopez I; University of Navarra, Center for Applied Medical Research, Program in Solid Tumors, Pamplona, Spain., Rodriguez-Remirez M; University of Navarra, Center for Applied Medical Research, Program in Solid Tumors, Pamplona, Spain., Palomino-Echeverria S; Navarrabiomed, Complejo Hospitalario de Navarra (CHN), Universidad Pública de Navarra, Pamplona, Spain., Lonfgren SM; Stanford Institute for Immunity, Transplantation and Infection, Stanford, CA, USA.; Stanford Center for Biomedical Informatics Research, Department of Medicine, Stanford University, Stanford, CA, USA., Ferrero M; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Molecular Oncology Laboratory, Fundación Para La Investigación del Hospital General Universitario de Valencia, Valencia, Spain.; Mixed Unit TRIAL (Principe Felipe Research Centre & Fundación para la Investigación del Hospital General Universitario de Valencia), Valencia, Spain., Calabuig S; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Molecular Oncology Laboratory, Fundación Para La Investigación del Hospital General Universitario de Valencia, Valencia, Spain.; Mixed Unit TRIAL (Principe Felipe Research Centre & Fundación para la Investigación del Hospital General Universitario de Valencia), Valencia, Spain.; Department of Pathology, Universitat de Valencia, Valencia, Spain., Ludwig IA; University of Navarra, Center for Applied Medical Research, Molecular Therapies Program, Pamplona, Spain., Lara-Astiaso D; University of Navarra, Center for Applied Medical Research, Genomics Platform, Pamplona, Spain., Jantus-Lewintre E; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; Molecular Oncology Laboratory, Fundación Para La Investigación del Hospital General Universitario de Valencia, Valencia, Spain.; Mixed Unit TRIAL (Principe Felipe Research Centre & Fundación para la Investigación del Hospital General Universitario de Valencia), Valencia, Spain.; Department of Pathology, Universitat de Valencia, Valencia, Spain., Guruceaga E; University of Navarra, Center for Applied Medical Research, Bioinformatics Platform, Pamplona, Spain.; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.; ProteoRed-Instituto de Salud Carlos III (ISCIII), Madrid, Spain., Narayanan S; University of Navarra, Center for Applied Medical Research, Program in Solid Tumors, Pamplona, Spain.; Clinica Universidad de Navarra, Department of Medical Oncology, Pamplona, Spain., Ponz-Sarvise M; University of Navarra, Center for Applied Medical Research, Program in Solid Tumors, Pamplona, Spain.; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.; Clinica Universidad de Navarra, Department of Medical Oncology, Pamplona, Spain., Pineda-Lucena A; University of Navarra, Center for Applied Medical Research, Molecular Therapies Program, Pamplona, Spain., Lecanda F; University of Navarra, Center for Applied Medical Research, Program in Solid Tumors, Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.; University of Navarra, Department of Pathology, Anatomy and Physiology, Pamplona, Spain., Ruggero D; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.; Department of Urology, University of California San Francisco, San Francisco, CA, USA.; Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA., Khatri P; Department of Urology, University of California San Francisco, San Francisco, CA, USA.; Navarrabiomed, Complejo Hospitalario de Navarra (CHN), Universidad Pública de Navarra, Pamplona, Spain., Santamaria E; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.; ProteoRed-Instituto de Salud Carlos III (ISCIII), Madrid, Spain., Fernandez-Irigoyen J; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.; ProteoRed-Instituto de Salud Carlos III (ISCIII), Madrid, Spain., Ferrer I; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; H12O-CNIO Lung Cancer Clinical Research Unit, Instituto de Investigación Hospital 12 de Octubre & Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain., Paz-Ares L; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; H12O-CNIO Lung Cancer Clinical Research Unit, Instituto de Investigación Hospital 12 de Octubre & Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain.; Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.; Medical School, Universidad Complutense, Madrid, Spain., Drosten M; Experimental Oncology Group, Molecular Oncology Program, Spanish National Cancer Center (CNIO), Madrid, Spain.; Molecular Mechanisms of Cancer Program, Centro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer, CSIC-University of Salamanca, Salamanca, Spain., Barbacid M; Experimental Oncology Group, Molecular Oncology Program, Spanish National Cancer Center (CNIO), Madrid, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Gil-Bazo I; University of Navarra, Center for Applied Medical Research, Program in Solid Tumors, Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.; Clinica Universidad de Navarra, Department of Medical Oncology, Pamplona, Spain.; Department of Oncology, Fundación Instituto Valenciano de Oncología, Valencia, Spain., Vicent S; University of Navarra, Center for Applied Medical Research, Program in Solid Tumors, Pamplona, Spain. silvevicent@unav.es.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. silvevicent@unav.es.; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain. silvevicent@unav.es.; University of Navarra, Department of Pathology, Anatomy and Physiology, Pamplona, Spain. silvevicent@unav.es.

Publikováno v: Nature communications [Nat Commun] 2023 Oct 10; Vol. 14 (1), pp. 6332. Date of Electronic Publication: 2023 Oct 10.

The phospholipid transporter PITPNC1 links KRAS to MYC to prevent autophagy in lung and pancreatic cancer.

Autor: Entrialgo-Cadierno R; Program in Solid Tumours, University of Navarra, Centre of Applied Medical Research (CIMA), 55 Pio XII Avenue, 31008, Pamplona, Spain., Cueto-Ureña C; Program in Solid Tumours, University of Navarra, Centre of Applied Medical Research (CIMA), 55 Pio XII Avenue, 31008, Pamplona, Spain., Welch C; Program in Solid Tumours, University of Navarra, Centre of Applied Medical Research (CIMA), 55 Pio XII Avenue, 31008, Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain., Feliu I; Program in Solid Tumours, University of Navarra, Centre of Applied Medical Research (CIMA), 55 Pio XII Avenue, 31008, Pamplona, Spain., Macaya I; Program in Solid Tumours, University of Navarra, Centre of Applied Medical Research (CIMA), 55 Pio XII Avenue, 31008, Pamplona, Spain., Vera L; Program in Solid Tumours, University of Navarra, Centre of Applied Medical Research (CIMA), 55 Pio XII Avenue, 31008, Pamplona, Spain., Morales X; Imaging Unit and Cancer Imaging Laboratory, University of Navarra, CIMA, Pamplona, Spain., Michelina SV; Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Centre, University of Torino, Turin, Italy., Scaparone P; Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Centre, University of Torino, Turin, Italy., Lopez I; Program in Solid Tumours, University of Navarra, Centre of Applied Medical Research (CIMA), 55 Pio XII Avenue, 31008, Pamplona, Spain., Darbo E; University of Bordeaux, INSERM, BRIC, U 1312, F-33000, Bordeaux, France., Erice O; Program in Solid Tumours, University of Navarra, Centre of Applied Medical Research (CIMA), 55 Pio XII Avenue, 31008, Pamplona, Spain., Vallejo A; Program in Solid Tumours, University of Navarra, Centre of Applied Medical Research (CIMA), 55 Pio XII Avenue, 31008, Pamplona, Spain., Moreno H; Program in Solid Tumours, University of Navarra, Centre of Applied Medical Research (CIMA), 55 Pio XII Avenue, 31008, Pamplona, Spain., Goñi-Salaverri A; Molecular Therapies Program, University of Navarra, CIMA, Pamplona, Spain., Lara-Astiaso D; Molecular Therapies Program, University of Navarra, CIMA, Pamplona, Spain.; Wellcome - MRC Cambridge Stem Cell Institute (CSCI), Cambridge, UK., Halberg N; Department of Biomedicine, University of Bergen, Bergen, Norway., Cortes-Dominguez I; Imaging Unit and Cancer Imaging Laboratory, University of Navarra, CIMA, Pamplona, Spain.; Bioinformatics Platform, University of Navarra, CIMA, Pamplona, Spain., Guruceaga E; Bioinformatics Platform, University of Navarra, CIMA, Pamplona, Spain.; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain., Ambrogio C; Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Centre, University of Torino, Turin, Italy., Lecanda F; Program in Solid Tumours, University of Navarra, Centre of Applied Medical Research (CIMA), 55 Pio XII Avenue, 31008, Pamplona, Spain.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.; Department of Pathology, Anatomy and Physiology, University of Navarra, Pamplona, Spain., Vicent S; Program in Solid Tumours, University of Navarra, Centre of Applied Medical Research (CIMA), 55 Pio XII Avenue, 31008, Pamplona, Spain. silvevicent@unav.es.; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain. silvevicent@unav.es.; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain. silvevicent@unav.es.; Department of Pathology, Anatomy and Physiology, University of Navarra, Pamplona, Spain. silvevicent@unav.es.

Publikováno v: Molecular cancer [Mol Cancer] 2023 May 20; Vol. 22 (1), pp. 86. Date of Electronic Publication: 2023 May 20.